December 2024. Volume 20. Number 4

Dupilumab is also effective for eosinophilic esophagitis in children under 12 years of age

 
 
 
 
 
 
 
 
 
 
Rating: 0 (0 Votes)
Newsletter Free Subscription
Regularly recieve most recent articles by e-mail
Subscribe
Print
Add to library
Discuss this article

AVC | Critically appraised articles

Chehade M, Dellon ES, Spergel JM, Collins MH, Rothenberg ME, Pesek RD, et al. Dupilumab for Eosinophilic Esophagitis in Patients 1 to 11 Years of Age. N Engl J Med. 2024;390:2239-51.

Reviewers: Pérez Solís D1, Pérez-Moneo Agapito B2.
1Servicio de Pediatría. Hospital Universitario San Agustín. Avilés. Asturias. España.
2Servicio de Pediatría. Hospital Universitario Infanta Leonor. Universidad Complutense de Madrid. Madrid. España.
Correspondence: David Pérez Solís. Email: david@perezsolis.es
Reception date: 21/10/2024
Acceptance date: 04/11/2024
Publication date: 13/11/2024

Abstract

Authors´ conclusions: dupilumab resulted in pathological remission in a significantly higher percentage of children with eosinophilic esophagitis than placebo.

Reviewers´ commentary: dupilumab is an effective treatment in paediatric patients with eosinophilic esophagitis. Due to its cost and limited experience of use, it should initially be reserved for patients who have been refractory to the rest of the available treatments.

How to cite this article

Pérez Solís D, Pérez-Moneo Agapito B. El dupilumab también es eficaz para la esofagitis eosinofílica en menores de 12 años. Evid Pediatr. 2024;20:47.

AVC | Critically appraised articles

Chehade M, Dellon ES, Spergel JM, Collins MH, Rothenberg ME, Pesek RD, et al. Dupilumab for Eosinophilic Esophagitis in Patients 1 to 11 Years of Age. N Engl J Med. 2024;390:2239-51.

Reviewers: Pérez Solís D1, Pérez-Moneo Agapito B2.
1Servicio de Pediatría. Hospital Universitario San Agustín. Avilés. Asturias. España.
2Servicio de Pediatría. Hospital Universitario Infanta Leonor. Universidad Complutense de Madrid. Madrid. España.
Correspondence: David Pérez Solís. Email: david@perezsolis.es
Reception date: 21/10/2024
Acceptance date: 04/11/2024
Publication date: 13/11/2024

How to cite this article

Pérez Solís D, Pérez-Moneo Agapito B. El dupilumab también es eficaz para la esofagitis eosinofílica en menores de 12 años. Evid Pediatr. 2024;20:47.

13/11/2024

Linked Comment